UCB (UCBJF) to Release Quarterly Earnings on Thursday

UCB (OTCMKTS:UCBJF) will likely be posting its resultson Thursday, July 30th. Analysts expect UCB to announce earnings of $5.81 per share and revenue of $4.6379 billion for the quarter.

UCB Stock Performance

UCBJF stock opened at $277.44 on Thursday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average price is $292.55 and its two-hundred day moving average price is $300.77. UCB has a fifty-two week low of $200.21 and a fifty-two week high of $345.39.

Analyst Upgrades and Downgrades

Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, UCB has a consensus rating of “Moderate Buy”.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.